Development
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy
Pharvaris N.V. (Nasdaq: PHVS) has reported an 83% reduction in monthly hereditary angioedema (HAE) attack rate with deucrictibant extended-release (XR)...
Beam reports durable BEAM-302 AAT restoration, advances pivotal cohort
Updated Phase I/II data from Beam Therapeutics' (Nasdaq: BEAM) BEAM-302 program, presented at the European Respiratory Society Congress in Barcelona, show...
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss
California-based Evommune, Inc. (NYSE: EVMN) revealed EVO756, an oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist, failed to meet its...
Insilico's IPF drug rentosertib shows biological age reversal in exploratory proteomic analysis
A new analysis published in Nature Biotechnology adds an unexpected dimension to the clinical profile of rentosertib, the AI-designed TNIK inhibitor from...
Semaglutide clears obesity treatment threshold in children aged 6 to under 12
Phase III data from Novo Nordisk's STEP Young trial show that once-weekly semaglutide (Wegovy, Ozempic, Rybelsus) reduced body mass index (BMI) in children...
AirNexis’s AN01 improves lung function on top of bronchodilators in COPD
A dual phosphodiesterase inhibitor delivered by dry powder inhaler met its primary endpoint in a Phase IIb randomized trial in chronic obstructive pulmonary...
Windward’s TSLP mAb shows six-month asthma activity after single dose
Positive Phase II interim data from SKB378/WIN378, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody engineered for extended half-life, have...
BMS’s GPRC5D CAR-T clears registrational trial in quadruple-exposed multiple myeloma
Arlocabtagene autoleucel met the primary endpoint of overall response rate (ORR) and all key secondary endpoints in the registrational QUINTESSENTIAL Phase...
Inhibrx's OX40 agonist nearly doubles response rate versus Keytruda alone in head and neck cancer
A hexavalent OX40 agonist that has struggled to find clinical traction across the broader class has now produced the first randomized efficacy signal for an...
Novo Nordisk scraps two Phase III ziltivekimab trials after ZEUS failure
Two large Phase III trials of ziltivekimab, Novo Nordisk's investigational IL-6 inhibitor, have been stopped early on the recommendation of an independent...
Amgen’s tarlatamab delivers Phase III OS win in first-line ES-SCLC maintenance
Adding tarlatamab to durvalumab maintenance produced a statistically significant and clinically meaningful improvement in overall survival in...
AZ’s tozorakimab shows Phase III benefit across eosinophil levels in COPD
Full Phase III results from the previously announced positive OBERON and TITANIA trials show that AstraZeneca's IL-33 antibody tozorakimab reduced...
Novartis’s pelacarsen misses Phase III endpoint despite deep Lp(a) lowering
Novartis’s pelacarsen failed to reduce major cardiovascular events in the Phase III Lp(a)HORIZON trial despite substantially lowering lipoprotein(a)...
Novartis’s Avidity-acquired del-desiran falls short in Phase III DM1 trial
The Phase III HARBOR study of delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) has failed its primary endpoint, dealing a major...
Argo's siRNA therapy cuts HAE attack rates 83–96% in small Phase II study
&x20;Argo Biopharmaceutical Co., Ltd. (Argo Biopharma) provided updated Phase II data for BW-20805, an investigational small interfering RNA (siRNA) therapy...
The AllSci Brief
Free, systematic R&D and deal news. Daily.